2 results
Approved WMOCompleted
* to describe the safety profile for qW, q2W and q3W regimens. * to determine the Maximum Tolerated Dose (MTD), if achieved (all regimens)* to describe the pharmacokinetics (PK) of single-agent RO6895882. Substudy BP28920/IMGThe study is designed to…
Approved WMORecruiting
The primary objective of this study is to determine if left atrial appendage closure with the WATCHMAN FLX device is a reasonablealternative to non-vitamin K oral anticoagulants (NOACs) in patients with non-valvular atrial fibrillation.